# Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

> **NCT03898180** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 505 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Placebo for lenvatinib

## Key facts

- **NCT ID:** NCT03898180
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2021-07-26
- **Final completion:** 2024-05-20
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03898180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03898180, "Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03898180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*